Biomedical Engineering Reference
In-Depth Information
64. Hansen RS, Diness TG, Christ T et al (2006) Activation of human ether-a-go-go-related gene
potassium channels by the diphenylurea 1,3-bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea
(NS1643). Mol Pharmacol 69:266-277
65. Hansen RS, Diness TG, Christ T et al (2006) Biophysical characterization of the new human
ether-a-go-go-related gene channel opener NS3623 [N-(4-bromo-2-(1H-tetrazol-5-yl)-
phenyl)-N
0
-(3
0
-trifluoromethylphenyl)urea]. Mol Pharmacol 70:1319-1329
66. Zeng H, Lozinskaya IM, Lin Z et al (2006) Mallotoxin is a novel human ether-a-go-go-
related gene (hERG) potassium channel activator. J Pharmacol Exp Ther 319:957-962
67. Lazzara R (1989) Amiodarone and torsade de pointes. Ann Intern Med 111:549-551
68. Zhou Z, Vorperian VR, Gong Q et al (1999) Block of HERG potassium channels by the
antihistamine astemizole and its metabolites desmethylastemizole and norastemizole.
J Cardiovasc Electrophysiol 10:836-843
69. Sadanaga T, Ogawa S (2007) Bepridil produces prominent bradycardia-dependent QT
prolongation in patients with structural heart disease. J Electrocardiol 40:426-431
70. Barrows B, Cheung K, Bialobrzeski T et al (2009) Extracellular potassium dependency of
block of HERG by quinidine and cisapride is primarily determined by the permeant ion and
not by inactivation. Channels (Austin) 3:239-248
71. Kamiya K, Niwa R, Morishima M et al (2008) Molecular determinants of hERG channel
block by terfenadine and cisapride. J Pharmacol Sci 108:301-307
72. Paakkari I (2002) Cardiotoxicity of new antihistamines and cisapride. Toxicol Lett 127:
279-284
73. Drolet B, Rousseau G, Daleau P et al (2000) Domperidone should not be considered a no-risk
alternative to cisapride in the treatment of gastrointestinal motility disorders. Circulation 102:
1883-1885
74. Claassen S, Zunkler BJ (2005) Comparison of the effects of metoclopramide and
domperidone on HERG channels. Pharmacology 74:31-36
75. Michael G, Dempster J, Kane KA et al (2007) Potentiation of E-4031-induced torsade de
pointes by HMR1556 or ATX-II is not predicted by action potential short-term variability or
triangulation. Br J Pharmacol 152:1215-1227
76. Esch JJ, Kantoch MJ (2008) Torsades de Pointes ventricular tachycardia in a pediatric patient
treated with fluconazole. Pediatr Cardiol 29:210-213
77. Han S, Zhang Y, Chen Q et al (2010) Fluconazole inhibits hERG K(+) channel by direct
block and disruption of protein trafficking. Eur J Pharmacol 650(1):138-144
78. Stark P, Fuller RW, Wong DT (1985) The pharmacologic profile of fluoxetine. J Clin
Psychiatry 46:7-13
79. Leonardi ET, Azmitia EC (1994) MDMA (ecstasy) inhibition of MAO type A and type B:
comparisons with fenfluramine and fluoxetine (Prozac). Neuropsychopharmacology 10:
231-238
80. Alvarez PA, Pahissa J (2010) QT alterations in psychopharmacology: proven candidates and
suspects. Curr Drug Saf 5:97-104
81. Stauderman KA, Gandhi VC, Jones DJ (1992) Fluoxetine-induced inhibition of synapto-
somal [3H]5-HT release: possible Ca(2+)-channel inhibition. Life Sci 50:2125-2138
82. Rae JL, Rich A, Zamudio AC et al (1995) Effect of Prozac on whole cell ionic currents in
lens and corneal epithelia. Am J Physiol 269:C250-C256
83. Backer JM, Wjasow C, Zhang Y (1997) In vitro binding and phosphorylation of insulin
receptor substrate 1 by the insulin receptor. Role of interactions mediated by the
phosphotyrosine-binding domain and the pleckstrin-homology domain. Eur J Biochem 245:
91-96
84. Rajamani S, Eckhardt LL, Valdivia CR et al (2006) Drug-induced long QT syndrome: hERG
K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine.
Br J Pharmacol 149:481-489
85. Varriale P (2001) Fluoxetine (Prozac) as a cause of QT prolongation. Arch Intern Med
161:612
